217.06 USD
-3.36 (-1.52%)
We assign a fundamental rating of 3 out of 10 to ASND. ASND was compared to 529 industry peers in the Biotechnology industry. Both the profitability and financial health of ASND have multiple concerns. ASND is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year ASND has reported negative net income.
ASND had a negative operating cash flow in the past year.
ASND had negative earnings in each of the past 5 years.
In the past 5 years ASND always reported negative operating cash flow.
1.2 Ratios
ASND has a Return On Assets of -20.17%. This is in the better half of the industry: ASND outperforms 75.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.17% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 86.80%, ASND belongs to the best of the industry, outperforming 89.04% of the companies in the same industry.
In the last couple of years the Gross Margin of ASND has grown nicely.
ASND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ASND has been increased compared to 1 year ago.
Compared to 5 years ago, ASND has more shares outstanding
The debt/assets ratio for ASND has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.06 indicates that ASND is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ASND (2.06) is better than 65.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.06 |
ROIC/WACCN/A
WACC6.68%
2.3 Liquidity
A Current Ratio of 1.03 indicates that ASND should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.03, ASND is doing worse than 88.28% of the companies in the same industry.
A Quick Ratio of 0.73 indicates that ASND may have some problems paying its short term obligations.
ASND's Quick ratio of 0.73 is on the low side compared to the rest of the industry. ASND is outperformed by 89.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.33% over the past year.
Looking at the last year, ASND shows a very strong growth in Revenue. The Revenue has grown by 97.46%.
ASND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 93.57% yearly.
EPS 1Y (TTM)48.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.86%
Revenue 1Y (TTM)97.46%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%269.4%
3.2 Future
Based on estimates for the next years, ASND will show a very strong growth in Earnings Per Share. The EPS will grow by 39.58% on average per year.
The Revenue is expected to grow by 57.68% on average over the next years. This is a very strong growth
EPS Next Y50.97%
EPS Next 2Y57.52%
EPS Next 3Y49.73%
EPS Next 5Y39.58%
Revenue Next Year128.79%
Revenue Next 2Y102.6%
Revenue Next 3Y79.34%
Revenue Next 5Y57.68%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ASND. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 58.53, the valuation of ASND can be described as expensive.
ASND's Price/Forward Earnings ratio is rather cheap when compared to the industry. ASND is cheaper than 89.98% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.79, ASND is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 58.53 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ASND's earnings are expected to grow with 49.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.52%
EPS Next 3Y49.73%
5. Dividend
5.1 Amount
No dividends for ASND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ASND (12/15/2025, 11:50:10 AM)
217.06
-3.36 (-1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners103.77%
Inst Owner Change4.31%
Ins Owners0.76%
Ins Owner ChangeN/A
Market Cap13.13B
Revenue(TTM)646.55M
Net Income(TTM)-232.94M
Analysts88.7
Price Target266.29 (22.68%)
Short Float %5.09%
Short Ratio6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-147.94%
Min EPS beat(2)-345.63%
Max EPS beat(2)49.75%
EPS beat(4)2
Avg EPS beat(4)-66.28%
Min EPS beat(4)-345.63%
Max EPS beat(4)49.75%
EPS beat(8)4
Avg EPS beat(8)-40.25%
EPS beat(12)6
Avg EPS beat(12)-28.09%
EPS beat(16)8
Avg EPS beat(16)-19.38%
Revenue beat(2)1
Avg Revenue beat(2)3.71%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)9.46%
Revenue beat(4)3
Avg Revenue beat(4)13.61%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)42.44%
Revenue beat(8)5
Avg Revenue beat(8)12.18%
Revenue beat(12)8
Avg Revenue beat(12)15.49%
Revenue beat(16)12
Avg Revenue beat(16)23.91%
PT rev (1m)2.01%
PT rev (3m)4.69%
EPS NQ rev (1m)-65.07%
EPS NQ rev (3m)210.56%
EPS NY rev (1m)-34.17%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)-7.32%
Revenue NQ rev (3m)-6.59%
Revenue NY rev (1m)-2.56%
Revenue NY rev (3m)-1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 58.53 | ||
| P/S | 17.31 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.53
EYN/A
EPS(NY)3.71
Fwd EY1.71%
FCF(TTM)-2.17
FCFYN/A
OCF(TTM)-2.07
OCFYN/A
SpS12.54
BVpS-3.38
TBVpS-3.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.17% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.8% | ||
| FCFM | N/A |
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 31.57% | ||
| Cap/Sales | 0.85% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 2.06 |
F-Score5
WACC6.68%
ROIC/WACCN/A
Cap/Depr(3y)33.9%
Cap/Depr(5y)97.41%
Cap/Sales(3y)9.88%
Cap/Sales(5y)130.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.86%
EPS Next Y50.97%
EPS Next 2Y57.52%
EPS Next 3Y49.73%
EPS Next 5Y39.58%
Revenue 1Y (TTM)97.46%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%269.4%
Revenue Next Year128.79%
Revenue Next 2Y102.6%
Revenue Next 3Y79.34%
Revenue Next 5Y57.68%
EBIT growth 1Y56.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.07%
EBIT Next 3Y52.74%
EBIT Next 5YN/A
FCF growth 1Y80.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.17%
OCF growth 3YN/A
OCF growth 5YN/A
ASCENDIS PHARMA A/S - ADR / ASND FAQ
Can you provide the ChartMill fundamental rating for ASCENDIS PHARMA A/S - ADR?
ChartMill assigns a fundamental rating of 3 / 10 to ASND.
What is the valuation status of ASCENDIS PHARMA A/S - ADR (ASND) stock?
ChartMill assigns a valuation rating of 2 / 10 to ASCENDIS PHARMA A/S - ADR (ASND). This can be considered as Overvalued.
What is the profitability of ASND stock?
ASCENDIS PHARMA A/S - ADR (ASND) has a profitability rating of 2 / 10.
What is the financial health of ASCENDIS PHARMA A/S - ADR (ASND) stock?
The financial health rating of ASCENDIS PHARMA A/S - ADR (ASND) is 2 / 10.